市场调查报告书
商品编码
1408046
全球 PCR 技术市场评估:按产品、技术、应用、最终用户、地区、机会、预测(2017-2031 年)Global PCR Technologies Market Assessment, By Product, By Technology, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球PCR技术市场规模预计到2023年将达到150.5亿美元,到2031年将达到297.5亿美元,2024-2031年预测期间复合年增长率为8.89%。我是。 分子生物学、生命科学和生物技术领域的市场正在快速成长。 由于PCR在临床疾病诊断和基因/分子检测中的使用越来越多,市场正在扩大。 近年来,需要PCR技术进行诊断的肝炎、流感、HIV感染和COVID-19等传染病的盛行率不断上升,推动了全球PCR技术市场的需求。
数位 PCR (dPCR) 和即时 PCR (qPCR) 等 PCR 技术的进步带来了试剂消耗更低、工作流程自动化以及更高的重现性和准确性等优势,推动了 PCR 技术的采用。推动市场成长。 新兴国家市场渗透率的提高和市场上有吸引力的机会正在导致融资和投资的增加。 随着投资者和市场参与者兴趣的增加,供给和需求都显着增加。 此外,政府对研发的支持也进一步促进了市场的发展。 然而,PCR设备的高成本、PCR技术的技术限制以及缺乏熟练的专业人员来执行协议是市场的主要限制因素。
肝炎、流感和爱滋病毒等传染病患者病率的增加是 PCR 技术市场的关键驱动因素。 传染病和遗传性疾病的增加导致对 PCR 技术的需求增加,因为它在这些疾病的诊断和监测中发挥重要作用。 PCR 广泛用于检测各种传染原,包括病毒、细菌和真菌,使其成为传染病管理的重要工具。 PCR技术也用于检测导致遗传性疾病的基因异常,进一步推动市场成长。
根据世界卫生组织的数据,截至 2022 年底,约有 3,900 万人感染爱滋病毒,其中包括约 150 万 0 至 14 岁的儿童。 季节性冬季流感可感染高达 20% 的人口并导致大量死亡。 根据世界卫生组织的数据,与季节性流感相关的呼吸道疾病每年导致全球 65 万人死亡。
PCR技术在临床诊断领域具有多种实际应用,近年来随着研究和开发的增加,PCR应用显着扩展。 PCR技术广泛用于COVID-19诊断,推动市场需求。 PCR 技术的显着应用包括广谱病原体检测、新兴传染病的评估和监测、生物威胁的早期检测以及抗菌素抗药性分析。 市场参与者正在针对 PCR 技术的新应用推出创新产品。
试剂和消耗品领域预计将在预测期内快速成长。 PCR检测所使用的设备是一次性投资,而试剂和耗材是重复消耗和购买的,这使其成为关键的收入驱动力。 引子、聚合□、核甘酸、反应缓衝液等试剂,以及孔板、吸头等耗材,在每次PCR过程中都会消耗殆尽,需要在下一次检测时重新填充,很难上市,我们正在获取经常性收入。
北美在全球 PCR 市场中占据主导地位,其中美国和加拿大占据最大的市场份额。 该地区的优势源自于广泛的研究基础设施和完善的监管框架等因素,可加快新疗法的批准。 该地区主要製药和生物技术公司的存在正在推动 PCR 技术的开发和采用。 此外,北美在 PCR 研究和开发方面吸引了大量投资,从而可以建立最先进的设施并获得先进技术。
本报告研究和分析了全球PCR技术市场,提供市场规模和预测、市场动态、主要公司趋势和展望等。
Global PCR technologies market size was valued at USD 15.05 billion in 2023, and is expected to reach USD 29.75 billion in 2031, with a CAGR of 8.89% for the forecast period between 2024 and 2031F. The Polymerase Chain Reaction technologies market is a rapidly growing field in molecular biology, life sciences, and biotechnology. The PCR technologies market is expanding owing to the increasing application of PCR in clinical disease diagnosis and genetic and molecular testing. The prevalence of infectious diseases like hepatitis, influenza, HIV infection, and COVID-19 infection which require PCR techniques for diagnosis, have been on the rise in recent years, driving demand in the global PCR technologies market.
Advancements in PCR techniques, such as digital PCR (dPCR) and real-time PCR (qPCR), offer benefits like low reagent consumption, automation of workflow, and greater reproducibility and precision, which are encouraging the adoption of PCR technologies, further fueling the market growth. Growing market penetration in emerging countries and attractive opportunities in the PCR technologies market have led to increased funding and investments. With increasing interest from investors and market players, the demand and supply both are significantly increasing. Additionally, government support for research and development is further encouraging market development. However, the high cost of PCR instruments, technical limitations of PCR technology, and lack of skilled professionals to perform the protocols are major restraints for the global PCR technologies market.
In November 2023, QIAGEN announced the launch of three new kits (QIAcuity Mycoplasma Quant Kit, QIAcuity OneStep Advanced EG Kit, and QIAcuity Mericon Food Testing Kits) for using them with its QIAcuity systems. The launch has a part where major new software updates are designed to expand the portfolio of applications for the use of dPCR technology in areas like cell and gene therapies, quantification of DNA and RNA, as well as food and pharmaceutical safety.
The increasing prevalence of infectious diseases like hepatitis, influenza, HIV is a significant driver for the PCR technologies market. The rise in infectious diseases and genetic diseases has led to a growing demand for PCR technologies, as they play a crucial role in the diagnosis and monitoring of these diseases. PCR is widely used in the detection of various infectious agents, including viruses, bacteria, and fungi, making it an indispensable tool in infectious disease management. PCR technologies are also used in the detection of genetic abnormalities causing genetic diseases, further fueling the market for growth.
According to WHO, about 39.0 million people were living with HIV at the end of 2022, including about 1.5 million children within the age group of 0 to 14 years. Seasonal influenza throughout the winter can infect up to 20% of the population and result in significant death. According to WHO data, respiratory illnesses associated with seasonal influenza causes up to 650,000 deaths globally each year.
PCR technology has several practical applications in the field of clinical diagnosis and in recent years, with increasing research and development, a significant expansion of PCR applications has been observed. PCR technology has been extensively utilized for COVID-19 diagnosis, driving demand in the market. Several notable applications of PCR technologies include broad-spectrum pathogen detection, assessment and surveillance of emerging infections, early detection of biological threat agents, and antimicrobial resistance analysis. Market players are coming up with innovative products for emerging applications of PCR technologies. In August 2022, GenScript USA Inc. launched a monkeypox virus PCR test kit, which was developed in partnership with Anbio Biotechnology. The kit was developed to address the monkeypox public health emergency in the United States.
Reagents and consumables segments are expected to grow at a fast rate in the forecasted period. The instruments used for PCR tests are one-time investments while the reagents and consumables are repeatedly consumed and purchased, which drives major revenue. Reagents like primers, polymerase, nucleotides, reaction buffers, and consumables like well plates and pipette tips are consumed completely in each PCR process and need to be refilled for the next test, drawing reoccurring revenue in the market.
North America dominates the global PCR market, with the United States and Canada holding largest market shares. The region's dominance is attributed to several factors, including extensive research infrastructure and a well-established regulatory framework that expedites approvals for new therapies. The presence of major pharmaceutical and biotechnology companies in the region has driven the development and adoption of PCR technologies. Additionally, North America has attracted significant investments in PCR research and development, enabling the establishment of state-of-the-art facilities and access to advanced technologies.
The market landscape for PCR technologies is growing with several key players contributing to its development and commercialization. The key players in this market include Bio-Rad Laboratories Inc., Merck KGaA, QIAGEN and others. These companies are involved in various growth strategies, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions to enhance their presence.
In September 2023, Bio-Rad Laboratories, Inc. announced the launch of two new PCR instruments named PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers. PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers are a novel addition to Bio-Rad Laboratories' portfolio of conventional PCR instruments. PTC Tempo 48/48 has the unique feature of two separate compartments with manual lids which allows two protocols to run simultaneously. The launch aims to support PCR applications in basic and translational research, process development, and quality control.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.